- Home
- SEVN vs SLRN Comparison
SEVN vs SLRN Comparison
Compare SEVN & SLRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- SLRN
- Stock Information
- Founded
- SEVN 1986
- SLRN 2020
- Country
- SEVN United States
- SLRN United States
- Employees
- SEVN N/A
- SLRN N/A
- Industry
- SEVN Real Estate Investment Trusts
- SLRN Biotechnology: Pharmaceutical Preparations
- Sector
- SEVN Real Estate
- SLRN Health Care
- Exchange
- SEVN Nasdaq
- SLRN Nasdaq
- Market Cap
- SEVN 167.7M
- SLRN 224.6M
- IPO Year
- SEVN N/A
- SLRN 2023
- Fundamental
- Price
- SEVN $11.62
- SLRN $2.41
- Analyst Decision
- SEVN Strong Buy
- SLRN Hold
- Analyst Count
- SEVN 4
- SLRN 5
- Target Price
- SEVN $14.50
- SLRN $9.60
- AVG Volume (30 Days)
- SEVN 47.5K
- SLRN 731.5K
- Earning Date
- SEVN 04-28-2025
- SLRN 05-16-2025
- Dividend Yield
- SEVN 11.99%
- SLRN N/A
- EPS Growth
- SEVN N/A
- SLRN N/A
- EPS
- SEVN 1.15
- SLRN N/A
- Revenue
- SEVN $30,074,000.00
- SLRN N/A
- Revenue This Year
- SEVN $14.73
- SLRN $267.11
- Revenue Next Year
- SEVN $5.39
- SLRN N/A
- P/E Ratio
- SEVN $10.16
- SLRN N/A
- Revenue Growth
- SEVN N/A
- SLRN N/A
- 52 Week Low
- SEVN $10.18
- SLRN $1.85
- 52 Week High
- SEVN $14.66
- SLRN $7.25
- Technical
- Relative Strength Index (RSI)
- SEVN 47.74
- SLRN 53.86
- Support Level
- SEVN $11.52
- SLRN $2.34
- Resistance Level
- SEVN $11.91
- SLRN $2.64
- Average True Range (ATR)
- SEVN 0.33
- SLRN 0.16
- MACD
- SEVN 0.06
- SLRN 0.02
- Stochastic Oscillator
- SEVN 66.34
- SLRN 67.83
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About SLRN ACELYRIN INC.
Acelyrin Inc is a late-stage clinical biopharmaceutical company. The clinical biopharma segment researches and develops treatments for diseases with pathology related to excess activation of the immune system. It is focused on providing patients with life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines.